Herantis Pharma plc and Renishaw plc sign collaboration agreement on Parkinson's study
(Thomson Reuters ONE) -
Herantis Pharma plc and Renishaw plc sign collaboration agreement on Parkinson's
study
Herantis Pharma Plc
Company release 25 Oct 2016 at 9:00 am
Herantis Pharma plc ("Herantis") and Renishaw plc ("Renishaw") have signed a
collaboration agreement related to the first clinical study of CDNF in
Parkinson's disease. Under the agreement, the Drug Delivery System developed by
Renishaw will be used for the clinical administration of CDNF. Herantis and
Renishaw will jointly contribute to funding of the clinical study and both
companies expect to independently benefit from the clinical data on CDNF and
Drug Delivery System respectively.
"Collaboration with Renishaw is extremely valuable for us," says Sigrid Booms,
Herantis' Director for Clinical Research. "In addition to benefitting from their
novel and innovative technology in the clinical study we will also get the
expertise and resources of an experienced global company."
Herantis and Renishaw are also partners in a consortium currently preparing an
approximately ?6 million grant agreement with the EU's Horizon 2020 framework
programme related to the clinical study. Clinical trial applications have been
submitted to regulatory authorities. Due to prolonged regulatory processes and
ongoing EU grant negotiations the study's planned launch of patient recruitment
has been postponed from end of 2016 to the first half of 2017.
Renishaw is a global company headquartered in the United Kingdom, with core
skills in measurement, motion control, healthcare, spectroscopy and
manufacturing. It develops innovative products that significantly advance its
customers' operational performance - from improving manufacturing efficiencies
and raising product quality, to maximizing research capabilities and improving
the efficacy of medical procedures.
The collaboration and schedule change do not impact the outlook or guidance of
Herantis.
Further information:
Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246
About Parkinson's disease
Parkinson's disease is a slowly progressing neurodegenerative disease caused by
the death of dopaminergic neurons in the brains. Common first symptoms of the
disease include tremors, rigidity and slowness of movement. While the motor
symptoms can be treated with medication the disease progression cannot be
prevented, and the benefits of medication may be lost with disease progression
or side effects can become unmanageable. In addition, Parkinson's disease may
cause non-motor symptoms such as sleep problems, depression, and anxiety, which
are not alleviated by current Parkinson's drugs. Estimated 7 million people
worldwide have Parkinson's disease.
About CDNF
CDNF, or Cerebral Dopamine Neurotrophic Factor, is an endoplasmic reticulum
located and secreted protein with neuroprotective and neurorestorative
properties, patented worldwide by Herantis. Following a preclinical development
program, which has showed it as efficacious in several preclinical models of
Parkinson's disease (PD), Herantis is preparing for a first-in-human clinical
study of CDNF in the treatment of PD and has a preclinical development program
for the treatment of ALS.
In preclinical studies including chronic toxicology studies, CDNF administration
has been safe; CDNF has protected and regenerated midbrain dopamine-generating
cells suggesting a potential for disease modification of PD; it has also shown
efficacy in non-motor symptoms in PD. In an ALS disease model CDNF has
significantly increased survival and reduced symptoms. This suggests the
potential to address unmet clinical needs in both PD and ALS. CDNF is based on
research at the Institute of Biotechnology at the University of Helsinki, lead
by professor Mart Saarma.
About Herantis Pharma Plc
Herantis Pharma Plc is a drug development company focused on early clinical
development of innovative drugs in unmet clinical needs. Our special emphasis is
in regenerative medicine where the company has two first-in-class assets based
on globally leading science in their fields: CDNF for neurodegenerative
diseases, primarily Parkinson's and ALS; and Lymfactin® for breast cancer
associated lymphedema, with potential also in primary lymphedema. The shares of
Herantis are listed on the First North Finland marketplace run by Nasdaq
Helsinki stock exchange.
Distribution:
Nasdaq Helsinki
Main media
www.herantis.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Herantis Pharma Oyj via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 25.10.2016 - 08:02 Uhr
Sprache: Deutsch
News-ID 502522
Anzahl Zeichen: 5616
contact information:
Town:
Helsinki
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Herantis Pharma plc and Renishaw plc sign collaboration agreement on Parkinson's study"
steht unter der journalistisch-redaktionellen Verantwortung von
Herantis Pharma Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
